{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:28:47Z","timestamp":1792189727663,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.neurobiolaging.2022.10.016","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T10:46:31Z","timestamp":1674038791000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["APOE differentially moderates cerebrospinal fluid and plasma phosphorylated tau181 associations with multi-domain cognition"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7931-1383","authenticated-orcid":false,"given":"Alexandra J.","family":"Weigand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla S.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Galasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Bondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4277-8876","authenticated-orcid":false,"given":"Kelsey R.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0001","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/joim.13332","article-title":"Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease","volume":"290","author":"Alawode","year":"2021","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0002","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2015.0098","article-title":"Effect of cognitive reserve on age-related changes in Cerebrospinal fluid biomarkers of Alzheimer Disease","volume":"72","author":"Almeida","year":"2015","journal-title":"JAMA Neurol"},{"issue":"5-6","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0003","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000481852","article-title":"APOE \u03b54 Genotype and Cognitive Reserve Effects on the Cognitive Functioning of Healthy Elders","volume":"44","author":"L\u00f3pez","year":"2017","journal-title":"Dement Geriatr. Cogn. Disord"},{"issue":"8","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0004","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.03.013","article-title":"APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline","volume":"22","author":"Bangen","year":"2013","journal-title":"J. Stroke Cerebrovasc. Dis"},{"issue":"6","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0005","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1212\/WNL.0000000000001834","article-title":"Mixed pathology is more likely in black than white decedents with Alzheimer dementia","volume":"85","author":"Barnes","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0006","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13195-021-00880-x","article-title":"Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals","volume":"13","author":"Biel","year":"2021","journal-title":"Alzheimers Res. Ther"},{"issue":"6","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0007","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/joim.12816","article-title":"Biomarkers for Alzheimer's disease: current status and prospects for the future","volume":"284","author":"Blennow","year":"2018","journal-title":"J. Intern. Med"},{"issue":"3","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0008","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3233\/JAD-170773","article-title":"The past and the future of Alzheimer's disease fluid biomarkers","volume":"62","author":"Blennow","year":"2018","journal-title":"J. Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0009","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1212\/WNL.0000000000012123","article-title":"Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease","volume":"97","author":"Boerwinkle","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/JAD-140276","article-title":"Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates","volume":"42","author":"Bondi","year":"2014","journal-title":"J. Alzheimers Dis"},{"issue":"9-10","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0011","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1017\/S135561771700100X","article-title":"Alzheimer's Disease: Past, Present, and Future","volume":"23","author":"Bondi","year":"2017","journal-title":"J. Int. Neuropsychol. Soc"},{"issue":"8","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0012","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0013","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/acn3.51529","article-title":"Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease","volume":"9","author":"Brickman","year":"2022","journal-title":"Ann. Clin. Transl. Neurol"},{"issue":"338","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0014","doi-asserted-by":"crossref","first-page":"338ra66","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer's disease","volume":"8","author":"Brier","year":"2016","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.neurobiolaging.2022.10.016_bib0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neurobiolaging.2022.02.015","article-title":"CSF phosphorylated tau as an indicator of subsequent tau accumulation","volume":"117","author":"Cogswell","year":"2022","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13195-019-0518-8","article-title":"Tau and atrophy: domain-specific relationships with cognition","volume":"11","author":"Digma","year":"2019","journal-title":"Alzheimers Res. Ther"},{"key":"10.1016\/j.neurobiolaging.2022.10.016_bib0017","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.dadm.2019.05.001","article-title":"Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease","volume":"11","author":"Fossati","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/WAD.0000000000000004","article-title":"Vascular risk factors and cognitive decline in a population sample","volume":"28","author":"Ganguli","year":"2014","journal-title":"Alzheimer Dis. Assoc. Disord"},{"issue":"3","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0019","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1567205014666170417111859","article-title":"Tau in Alzheimer's Disease: mechanisms and Therapeutic Strategies","volume":"15","author":"Gao","year":"2018","journal-title":"Curr. Alzheimer Res"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0020","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1038\/s41467-020-18198-x","article-title":"Association of APOE e2 genotype with Alzheimer's and non-Alzheimer's neurodegenerative pathologies","volume":"11","author":"Goldberg","year":"2020","journal-title":"Nat. Commun"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0021","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13195-021-00834-3","article-title":"Characterization of Alzheimer's tau biomarker discordance using plasma, CSF, and PET","volume":"13","author":"Guo","year":"2021","journal-title":"Alzheimers Res. Ther"},{"issue":"5","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0023","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/JGP.0b013e31819431d5","article-title":"Quantification of five neuropsychological approaches to defining mild cognitive impairment","volume":"17","author":"Jak","year":"2009","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0024","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","article-title":"Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease","volume":"11","author":"Janelidze","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0025","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat. Med"},{"issue":"2","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0027","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","article-title":"Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative","volume":"26","author":"Karikari","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2022.10.016_bib0028","unstructured":"Landau S, Murphy AE, Lee JQ, et\u00a0al. Florbetaben (FBB) processing methods. 2021a. Available at: https:\/\/adni.loni.usc.edu\/data-samples\/access-data\/. Accessed August 15, 2022."},{"key":"10.1016\/j.neurobiolaging.2022.10.016_bib0029","unstructured":"Landau S, Murphy AE, Lee JQ, et\u00a0al. Florbetapir (AV45) processing methods. 2021b. Available at: https:\/\/adni.loni.usc.edu\/data-samples\/access-data\/. Accessed August 15, 2022."},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0030","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1212\/WNL.0000000000007728","article-title":"Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults","volume":"93","author":"Lowe","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0031","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/brain\/awx320","article-title":"Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia","volume":"141","author":"Lowe","year":"2018","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0032","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","article-title":"Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes","volume":"78","author":"Mielke","year":"2021","journal-title":"JAMA Neurol"},{"issue":"7806","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0033","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","article-title":"APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline","volume":"581","author":"Montagne","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0034","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/alz.12570","article-title":"CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design","volume":"18","author":"Moscoso","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0035","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/brain\/awaa399","article-title":"Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum","volume":"144","author":"Moscoso","year":"2021","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0036","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0037","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jamaneurol.2021.4417","article-title":"Research criteria for the behavioral variant of Alzheimer Disease: a systematic review and meta-analysis","volume":"79","author":"Ossenkoppele","year":"2022","journal-title":"JAMA Neurol"},{"issue":"24","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0038","doi-asserted-by":"crossref","first-page":"e2127","DOI":"10.1212\/WNL.0000000000005677","article-title":"APOE \u03b52\u03b54 genotype, incident AD and MCI, cognitive decline, and AD pathology in older adults","volume":"90","author":"Oveisgharan","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0039","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","article-title":"Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures","volume":"27","author":"Palmqvist","year":"2021","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","article-title":"Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization","volume":"74","author":"Petersen","year":"2010","journal-title":"Neurology"},{"issue":"3-4","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0041","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/17588928.2013.831820","article-title":"Relationship of cognitive reserve and APOE status to the emergence of clinical symptoms in preclinical Alzheimer's disease","volume":"4","author":"Pettigrew","year":"2013","journal-title":"Cogn. Neurosci"},{"issue":"3","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0042","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3233\/JAD-210673","article-title":"Association of APOE \u025b4 and Plasma p-tau181 with Preclinical Alzheimer's Disease and Longitudinal change in Hippocampus Function","volume":"85","author":"Salami","year":"2022","journal-title":"J. Alzheimers Dis"},{"key":"10.1016\/j.neurobiolaging.2022.10.016_bib0043","unstructured":"Shaw LM, Figurski M, Berlas S, et\u00a0al. ADNI3 second BATCH CSF analyses of Ab1-42, Ab1-40, t-tau and ptau181 using the automated Roche Elecsys and cobas e 601 immunoassay analyzer system. 2022. Available at: https:\/\/adni.loni.usc.edu\/data-samples\/access-data\/. Accessed August 15, 2022."},{"key":"10.1016\/j.neurobiolaging.2022.10.016_bib0044","unstructured":"Shaw LM, Figurski M, Fields L, et\u00a0al. ADNI3: Batch analsyses of Ab1-42, t-tau, and ptau181 in ADNI1 and ADNIGO\/2 CSF using the fully automated Roche Elecsys and cobas e immunoassay analyzer system. 2017. Available at: https:\/\/adni.loni.usc.edu\/data-samples\/access-data\/. Accessed August 15, 2022."},{"issue":"7673","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0045","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","article-title":"ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy","volume":"549","author":"Shi","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0046","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","article-title":"PET imaging of Tau Deposition in the aging human brain","volume":"89","author":"Sch\u00f6ll","year":"2016","journal-title":"Neuron"},{"issue":"9","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0047","doi-asserted-by":"crossref","first-page":"e950","DOI":"10.1212\/WNL.0000000000008864","article-title":"White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease","volume":"94","author":"Soldan","year":"2020","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.neurobiolaging.2022.10.016_bib59","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012921","article-title":"Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected","volume":"12","author":"Su\u00e1rez-Calvet","year":"2020","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0048","first-page":"e81","article-title":"Topographic distribution of Amyloid-\u03b2, Tau, and Atrophy in patients with behavioral\/Dysexecutive Alzheimer disease","volume":"96","author":"Su\u00e1rez-Calvet","year":"2021","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0049","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0050","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jalz.2019.06.4948","article-title":"MCI-to-normal reversion using neuropsychological criteria in the Alzheimer's Disease Neuroimaging Initiative","volume":"15","author":"Thomas","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0051","doi-asserted-by":"crossref","first-page":"e12238","DOI":"10.1002\/dad2.12238","article-title":"Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease-related declines","volume":"13","author":"Thomas","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0052","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3233\/JAD-200496","article-title":"White matter Hyperintensities are no major confounder for Alzheimer's Disease Cerebrospinal fluid biomarkers","volume":"79","author":"van Waalwijk","year":"2021","journal-title":"J. Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0053","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000209965","article-title":"Impact of vascular risk factors and diseases on cognition in persons with mild cognitive impairment","volume":"27","author":"Villeneuve","year":"2009","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"10.1016\/j.neurobiolaging.2022.10.016_bib0054","article-title":"Plasma p-tau181 Level predicts Neurodegeneration and progression to Alzheimer's Dementia: a longitudinal study","volume":"12","author":"Wang","year":"2021","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_bib0056","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/alz.12173","article-title":"APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia","volume":"17","author":"Weigand","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurobiolaging.2022.10.016_bib0057","unstructured":"Zetterberg H, Blennow K. ADNI 1\/GO\/2 longitudinal plasma p-tau181. 2021. Available at: https:\/\/adni.loni.usc.edu\/data-samples\/access-data\/. Accessed August 15, 2022."},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.10.016_sbref0058","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13041-019-0448-1","article-title":"Blood-based molecular biomarkers for Alzheimer's disease","volume":"12","author":"Zetterberg","year":"2019","journal-title":"Mol. Brain"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458023000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458023000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:43:23Z","timestamp":1759319003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458023000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":57,"alternative-id":["S0197458023000040"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2022.10.016","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"APOE differentially moderates cerebrospinal fluid and plasma phosphorylated tau181 associations with multi-domain cognition","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2022.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}